首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >Adaptive Design for Diabetes Clinical Trials: Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

【2h】

Adaptive Design for Diabetes Clinical Trials: Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

机译：糖尿病临床试验的自适应设计：自适应设计方法论在长效胰高血糖素样肽1类似物（杜拉鲁肽）开发中的应用：统计设计和模拟

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundDulaglutide (dula, LY2189265), a long-acting glucagon-like peptide-1 analog, is being developed to treat type 2 diabetes mellitus.

机译：背景：长效胰高血糖素样肽1类似物杜拉鲁肽（dula，LY2189265）正在开发中，用于治疗2型糖尿病。

著录项

期刊名称 Journal of Diabetes Science and Technology
作者
Zachary Skrivanek; Scott Berry; Don Berry; Jenny Chien; Mary Jane Geiger; James H. Anderson Jr.; Brenda Gaydos;
展开▼
作者单位

展开▼
年(卷),期 2012(6),6
年度 2012
页码 1305–1318
总页数 14
原文格式 PDF
正文语种
中图分类基础医学;
关键词
adaptive dose finding dulaglutide GLP-1 seamless design;

机译：自适应剂量发现;度拉鲁肽;GLP-1;无缝设计;
入库时间 2022-08-17 11:54:21

相似文献

外文文献
中文文献
专利

1. Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations [J] . Zachary Skrivanek, Scott Berry, Don Berry, Journal of Diabetes Science and Technology . 2012,第6期

机译：自适应设计方法论在长效胰高血糖素样肽1类似物（杜拉鲁肽）开发中的应用：统计设计和模拟
2. An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics [J] . Mary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, Journal of Diabetes Science and Technology . 2012,第6期

机译：长效胰高血糖素样肽1类似物（杜拉鲁肽）的自适应剂量发现无缝2/3期研究：试验设计和基线特征
3. From Adaptive Design to Modern Protocol Design for Drug Development: Part I. Editorial and Summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum [J] . Sue Jane WangFrank Bretz Drug information journal . 2010,第3期

机译：从自适应设计到药物开发的现代方案设计：第一部分。第三届FDA / DIA统计论坛上自适应设计的编辑和摘要
4. Adaptive Enrichment Design: Development and Methodology - An Adaptive Approach Using a Phase 3 Clinical Trial with Two Subpopulations in a Confirmatory Setting [C] . Shariq Alavi, Rika Alavi, Pranab Ghosh, Molecular Medicine TRI-CON. . 2014

机译：自适应浓缩设计：开发和方法 - 一种使用阶段3临床试验的适应性方法，在确认设置中的两个亚步骤
5. Two stage adaptive optimal design with applications to dose-finding clinical trials. [D] . Lane, Adam. 2013

机译：两阶段自适应优化设计，可用于剂量寻找临床试验。
6. Adaptive Design for Diabetes Clinical Trials: An Adaptive Dose-Finding Seamless Phase 2/3 Study of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics [O] . Mary Jane Geiger, Zachary Skrivanek, Brenda Gaydos, 2012

机译：糖尿病临床试验的自适应设计：长效胰高血糖素样肽-1类似物（杜拉鲁肽）的自适应剂量发现无缝2/3期研究：试验设计和基线特征
7. Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations [O] . Zachary Skrivanek, Scott Berry, Don Berry, 2012

机译：自适应设计方法在长效胰高血糖素样肽-1模拟（杜拉格粉酯）的应用中的应用：统计设计和模拟

Adaptive Design for Diabetes Clinical Trials: Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-Like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations

摘要

著录项

相似文献

相关主题

期刊订阅